{"denoms":[{"counts":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"379"},{"groupId":"BG002","value":"573"}],"units":"Participants"}],"groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best supportive care (BSC).","id":"BG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"BG001","title":"Regorafenib 160 mg (BAY73-4506)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.6","value":"61.1"},{"groupId":"BG001","spread":"12.4","value":"61.8"},{"groupId":"BG002","spread":"12.1","value":"61.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"69"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"333"},{"groupId":"BG002","value":"504"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"247"},{"groupId":"BG002","value":"377"}],"title":"ECOG PS 0"},{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"196"}],"title":"ECOG PS 1"}]}],"description":"ECOG PS was measured in a scale from 0 (best) to grade 4 (worst), where 0= Fully active, able to carry on all pre-diseases performance without restriction, 1= Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2= Ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50 percent (%) waking hours (h), 3= Capable of only limited self-care, confined to bed/chair, more than 50% waking hours, and 4= Completely disabled, cannot carry on any self-care, totally confined to bed/chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern cooperative oncology group (ECOG) Performance Status (PS) (data collection system-RAVE)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"251"},{"groupId":"BG002","value":"380"}],"title":"ECOG PS 0"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"193"}],"title":"ECOG PS 1"}]}],"description":"ECOG PS was measured in a scale from 0 (best) to grade 4 (worst), where 0= Fully active, able to carry on all pre-diseases performance without restriction, 1= Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2= Ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50 % waking h, 3= Capable of only limited self-care, confined to bed/chair, more than 50% waking hours, and 4= Completely disabled, cannot carry on any self-care, totally confined to bed/chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG PS: Interactive voice response system (IVRS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"324"}],"title":"less than (<) 400 nanogram per milliliter (ng/mL)"},{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"249"}],"title":"greater than or equal to (>=) 400 ng/mL"}]}],"description":"Alpha-Fetoprotein blood test was performed and baseline data were reported.","paramType":"COUNT_OF_PARTICIPANTS","title":"Alpha-fetoprotein (AFP) (RAVE)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"317"}],"title":"< 400 ng/mL"},{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"256"}],"title":">= 400 ng/mL"}]}],"description":"AFP blood test was performed and baseline data were reported.","paramType":"COUNT_OF_PARTICIPANTS","title":"Alpha-fetoprotein (AFP) (IVRS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"409"}],"title":"Absence"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"164"}],"title":"Presence"}]}],"description":"Macrovascular invasion was defined as presence or absence of invasion of portal or hepatic vasculature by tumor.","paramType":"COUNT_OF_PARTICIPANTS","title":"Macrovascular invasion (RAVE)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"397"}],"title":"Absence"},{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"176"}],"title":"Presence"}]}],"description":"Macrovascular invasion was defined as presence or absence of invasion of portal or hepatic vasculature by tumor.","paramType":"COUNT_OF_PARTICIPANTS","title":"Macrovascular invasion (IVRS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Early stage"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"75"}],"title":"Intermediate stage"},{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"325"},{"groupId":"BG002","value":"497"}],"title":"Advanced stage"}]}],"description":"BCLC classification divides HCC subjects in 5 stages (0=very early stage, A=early stage, B=intermediate stage, C=advanced stage and D=terminal stage) according to pre-established prognostic variables, and allocates therapies according to treatment-related status. Thus, it provides information on both prognostic prediction and treatment allocation.","paramType":"COUNT_OF_PARTICIPANTS","title":"The Barcelona-Clinic Liver Cancer (BCLC) stage at study entry","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"161"}],"title":"Absence"},{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"412"}],"title":"Presence"}]}],"description":"Extrahepatic disease defined as presence or absence of tumor outside the liver.","paramType":"COUNT_OF_PARTICIPANTS","title":"Extrahepatic disease (RAVE)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"191"}],"title":"Absence"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"250"},{"groupId":"BG002","value":"382"}],"title":"Presence"}]}],"description":"Extrahepatic disease defined as presence or absence of tumor outside the liver.","paramType":"COUNT_OF_PARTICIPANTS","title":"Extrahepatic disease (IVRS)","unitOfMeasure":"Participants"}]}